Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
SAN DIEGO, Feb. 15, 2017 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, will announce its financial results for the fourth quarter and full year ending December 31, 2016, before the market opens on Thursday, February 23, 2017.
The company will hold a conference call and simultaneous webcast at 8:30 AM Eastern Time (5:30 AM Pacific Time) on Thursday, February 23, 2017 to discuss the company's financial results and provide a business update. Interested parties may access the conference call by dialing (844) 889-7791 (U.S) or (661) 378 9934 (international) using passcode 69450068. Media and individuals will be in a listen-only mode. Participants are asked to dial in a few minutes prior to the call to register for the event. The conference call will also be webcast live at: http://edge.media-server.com/m/p/su8exugw
A replay of the call will be available through March 2, 11:30 am EST by calling (855) 859-2056 (U.S.) or (404) 537-3406 (international), using passcode 69450068. An archive of the webcast will be available for twelve months following the event on Obalon Therapeutics website located at http://investor.obalon.com in the “News & Events” section.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN), is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
For Obalon Therapeutics Inc. Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 [email protected] Media: Megan Driscoll EvolveMKD Office Phone: +1 646 517 4220 [email protected]
